Oculus posts record sales in fourth quarter

Petaluma medical technology startup Oculus Innovative Sciences saw sales rise 23 percent to a record $2.7 million in the fourth quarter, company officials said Thursday.

Oculus lost $1.7 million in the quarter, up 13 percent from the same period last year.

Oculus makes an infection-fighting liquid called Microcyn that is sold in the U.S., Mexico, Europe, India, China and parts of the Middle East.

Microcyn products are aimed at the dermatology, wound care, oral care, cosmeceutical and veterinary care markets.

Oculus is partnering with drug development companies to launch prescription versions in the U.S.

Sales grew in the U.S., Mexico, Europe and China during the quarter ended March 31, offset by declines in India and the Middle East.

Expenses rose 22 percent, driven by research and development and regulatory costs.

For the full year, Oculus posted a $7.9 million loss on $9.8 million in sales.

Oculus has about 35 employees at its Petaluma headquarters.